Applied Finance Capital Management LLC Sells 1,027 Shares of Thermo Fisher Scientific Inc. $TMO

Applied Finance Capital Management LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% during the 1st quarter, Holdings Channel reports. The institutional investor owned 23,356 shares of the medical research company’s stock after selling 1,027 shares during the period. Applied Finance Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $11,480,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Assetmark Inc. lifted its position in shares of Thermo Fisher Scientific by 22.9% during the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after purchasing an additional 7,023 shares during the last quarter. North Dakota State Investment Board purchased a new position in Thermo Fisher Scientific in the 4th quarter worth about $7,505,000. EdgePoint Investment Group Inc. lifted its holdings in Thermo Fisher Scientific by 5.0% during the 3rd quarter. EdgePoint Investment Group Inc. now owns 1,388,662 shares of the medical research company’s stock valued at $673,529,000 after buying an additional 65,597 shares in the last quarter. Confluence Investment Management LLC raised its stake in shares of Thermo Fisher Scientific by 14.2% during the fourth quarter. Confluence Investment Management LLC now owns 95,064 shares of the medical research company’s stock valued at $55,085,000 after acquiring an additional 11,841 shares in the last quarter. Finally, Focus Partners Wealth grew its position in shares of Thermo Fisher Scientific by 1.2% during the 3rd quarter. Focus Partners Wealth now owns 258,747 shares of the medical research company’s stock worth $125,514,000 after buying an additional 2,947 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by insiders.

Analysts Set New Price Targets

TMO has been the subject of several analyst reports. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Sanford C. Bernstein began coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They set a “market perform” rating and a $520.00 price objective on the stock. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. Finally, Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $602.14.

Thermo Fisher Scientific Stock Performance

TMO opened at $526.72 on Monday. The company has a market cap of $195.74 billion, a price-to-earnings ratio of 28.96, a PEG ratio of 2.33 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 52-week low of $403.36 and a 52-week high of $643.99. The firm’s fifty day simple moving average is $478.23 and its two-hundred day simple moving average is $516.03. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s payout ratio is 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.